05.02.2014:

Tiltan Pharma Raises $1.5 Million.

The capital is intended for the completion of the ongoing Phase 2 clinical trial of TL-118, for the treatment of metastatic pancreatic cancer.

Read more...

13.11.2012:

Tiltan Pharma Announces Enrollment of First U.S. Patient

In A Phase 2 Clinical Trial of TL-118, Anti-Angiogenic Treatment For Metastatic Pancreatic Cancer.

Read more...

30.10.2012:

YISSUM BIOTECH HOLDING CO INTEGRA RAISES $7M

TO BE INVESTED IN YISSUM HOLDING COMPANIES INCLUDING TILTAN PHARMA.

Globes.

Read more...

17.07.2012:

Tiltan Pharma Receives FDA Approval

To Conducts Its Phase 2 Clinical Study Of Anti-Angiogenic Treatment For Pancreatic Cancer In The US.

Globes.

Read more...

13.02.2012:

Tiltan Pharma Commences Phase 2 Clinical Study

of Anti-Angiogenic Treatment for Pancreatic Cancer.

News1.

Read more...

22.06.2011:

YISSUM ANNOUNCES TILTAN PHARMA TO BE ONE OF THE LEADING PORTFOLIO COMPANIES OF ITS NEW HOLDING COMPANY INTEGRA HOLDINGS.

Globes.

Read more...

21.12.2010:

FDA Approves Tiltan’s Investigational New Drug (IND) Clinical Trial Program.

Read more...

26.04.2007:

Tiltan Has Developed An Anti-Cancer Platform That Attacks The Cancer's Supply Line Instead of The Growth Itself.

Globes.

Read more...

Built by Badboy.co.il

© copyright 2015 Tiltan Pharma